

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
MEETING SUMMARY
February 7, 2007**

Opening Remarks/Introductions

The Medicaid Pharmacy Prior Authorization (PA) Advisory Committee met on February 7, 2007, to review 32 drug classes for the Wisconsin Medicaid preferred drug list (PDL).

Kevin Hayden, Secretary of the Department of Health and Family Services (DHFS), opened the meeting by reviewing the agenda and the following items:

- A reminder to Committee members to complete the Nondisclosure and Conflict of Interest forms. Members of the Committee are asked to complete the form and disclose any possible conflicts of interest for each meeting.
- A reminder to those testifying during public comment to complete the Presenter/Witness Disclosure form and provide it to DHCF staff at the registration table.

Review/Approval of August 16, 2006, Meeting Summary

The meeting summary was distributed to the Committee members. Secretary Hayden requested modifications or a motion to approve the summary. Motion was made to approve the summary by Ms. Barber and seconded by Ms. Walker.

There were no votes opposed and no abstentions.

Secretary Hayden suggested that because the meetings occur every six months, the Committee receive, review, and approve the meeting summaries via email. Motion was made to approve future meeting summaries via email by Dr. Fedderly and seconded by Dr. Izard.

There were no votes opposed and no abstentions.

Follow-up from August 16, 2006 Meeting

After public testimony, Secretary Hayden asked Dr. Mergener to provide an update on the follow-up items from the August 16, 2006 meeting.

- Dr. Mergener summarized the PDL recommendations and the Secretary's decisions. In the Leukotriene Modifiers class, the Committee recommended DHCF staff conduct analysis to determine if there is appropriate use of the drugs in the class related to allergic rhinitis. The Committee encouraged the Secretary to adopt appropriate restrictions that would limit the use of the drugs in the class to asthma or COPD.
 - Dr. Mergener presented an analysis that indicated that there are a limited number of recipients using the Leukotriene Modifiers inappropriately
 - Based on the findings, DHCF staff recommended referring the issue to the DUR Board for a targeted intervention for prescribers.
- The Committee requested the DHCF staff analyze the effectiveness of the current emergency fill process and report back at the next meeting. The Committee also recommended that

DHCF staff take steps to better educate pharmacies and prescribers on the emergency drug fill policy and procedure.

Staff analyzed the process and found that currently very few pharmacies use the process. Based on the feedback from the Committee DHCF staff created a publication for pharmacies to re-educate and communicate the policy and process. The publication is posted to the DHCF website.

- Dr. Hirsch recommended the State conduct a PDL audit to ensure the PDL policy and procedures are being adhered to appropriately by prescribers and pharmacies.

State staff met to determine the best method for determining compliance with the PDL policy. Staff developed compliance graphs for PDL drug classes to determine if changing market share occurs when changes are made to the PDL. The analysis shows a significant market share shift following PDL implementations when no grandfathering occurs. Based on the analysis, the State is not recommending an audit be conducted. Because of the high level of compliance, it is unlikely the State would achieve a return on its investment.

Following the discussion Dr. Hirsch asked what the current status of Tamiflu is on the Wisconsin PDL. Staff stated the current status of Tamiflu is preferred.

Public Testimony

Secretary Hayden reviewed the testimony guidelines for the meeting.

Secretary Hayden also announced that speakers are welcome to remain for the ‘open’ Committee deliberation in the afternoon as Committee members may question speakers that provided testimony.

The table below lists each speaker and the topic of their testimony:

SUMMARY OF PUBLIC TESTIMONY

Scheduled Time	Name	Company	Product/Class	Notes
8:45	Russ Sobotta	Sanofi-aventis	Avapro/Avalide (irbesartan) / Angiotensin Receptor Blockers Ambien, Ambien CR (zolpidem extended release) / Sedative Hypnotics	Include Avalide, Ambien, and Ambien CR on the PDL. Presented efficacy, and clinical trials.
8:50	Dr. Randy Heidel	Daiichi Sankyo	Benicar (olmesartan) / Angiotensin Receptor Blockers	Testified on behalf of himself and his patients. Presented compliance, tolerability, efficacy, trials, and cost advantages over other products

Scheduled Time	Name	Company	Product/Class	Notes
				in the class.
8:55	Jamie Hurst	AstraZeneca	Nexium (esomeprazole) / Proton Pump Inhibitor Crestor (rosuvastatin) / Lipotropics, Statins	Presented general efficacy and indications for Crestor. Presented age specific indications and efficacy for Nexium.
9:00	Scott Conry PharmD	Merck/Schering Plough	Vytorin (simvastatin, ezetimibe) / Lipotropics, Statins Zetia (ezetimibe) / Lipotropics, Other	Presented efficacy and clinical trial superiority for Vytorin over simvastatin, Lipitor, and Crestor. Presented clinical effectiveness, unique indications, and safety advantages for Zetia.
9:05	Dr. Suhail Allaqaband Mike Asmus	Pfizer, Inc.	Lipitor (atrovastatin) / Lipotropics, Statins	Presented superiority of preventing cardiovascular events and lowering LDL levels as compared to other drugs in the class. Presented safety advantages.
9:10	Seonyoung Ryu	Amgen	Aranesp (darbepoetin) / Erythropoiesis Stimulating Proteins	Presented indication for anemia, pediatric dosing, chemotherapy dosing, efficacy, and auto-injector for Aranesp.
9:15	Maureen Kubiacki	Johnson & Johnson	Procrit (epoetin) / Erythropoiesis Stimulating Proteins	Presented four FDA approved indications for anemia (two unique). Presented dosing frequency advantages for Procrit.
9:20	Joseph Jares, M.D.	Epilepsy Foundation	Anticonvulsants	Spoke in support of not restricting physician prescribing options for Anticonvulsant class because of differing side effects and efficacy of drugs in the class.
9:25	Ann Faulkes	Consumer	Anticonvulsants	Presented personal experience of using epilepsy drugs for the past 35 years. Spoke in support of not restricting physician access because of differing side effects,

Scheduled Time	Name	Company	Product/Class	Notes
				mechanisms of action, and efficacy.
9:30	Vanessa Jacobsen	Ortho-McNeil, Inc.	Topamax (topiramate) / Anticonvulsants	Presented patient preference, efficacy, side effect profile, and tolerability advantages..
9:35	Rose Mullen	Eli Lilly	Cymbalta (duloxetine) / Antidepressants, Other	Presented unique indication for diabetic neuropathic pain, efficacy, and rapid onset of action.
9:40	Manish Puri	Wyeth Pharmaceuticals	Effexor XR (venlafaxine SR) / Antidepressants, Other	Presented uses, efficacy, dual-action, safety, and tolerability advantages..
9:45	Dr. Anna Cothron	Takeda Pharmaceuticals	Rozerem (ramelteon) / Sedative Hypnotics	Testifying as an advocate for her patients. Rozerem has fewer addiction properties and a low risk of toxicity with fewer drug-drug interactions.
9:50	Earl Beam, PA-C	Alpharma	Kadian (morphine ER) / Analgesics, Narcotics, long acting	Presented efficacy, tolerability and cost advantages for Kadian over other drugs in the class.
9:55	Dr. Allan Rifkin	Advocate	Antimigraine Agents, Triptans	Spoke in support of not restricting prescribing options for Triptans due to differing side effects, mechanisms of action, and efficacy. Spoke highly in support of Imitrex.
10:00	LaGenia Bailey	Bristol-Myers Squibb	Emsam (selegeline) / Antidepressants, Other	Presented efficacy, indications, safety, contraindications, and side effect information.
10:05	Anthony Pagedas	Abbott	Tricor (fenofibrate) / Lipotropics, Other	Presented efficacy, safety data for diabetic patients.
10:10	Traci Purath	Advocate – CHS Comprehensive Headache Center	Antimigraine Agents, Triptans	Spoke in support of not restricting prescribing options for Triptans due to differing side effects, mechanisms of action, and efficacy. Spoke highly in support of Relpax.
	BREAK			
10:30	Wolfram Nolten, M.D.	Advocate	Hypoglycemics, Thiazolidinediones	Presented efficacy, adherence, patient cost, and plan cost advantages for combination

Scheduled Time	Name	Company	Product/Class	Notes
				diabetic products..
10:35	Dr. Vishnu Bahkta Murthy	Advocate	Hypoglycemics, Thiazolidinediones	Spoke in support of not restricting physician prescribing options for TZD class.
10:40	Monica Fay	UCB Pharma	Keppra (levetiracetam) / Anticonvulsants	Presented indications for epilepsy, route of administration, unique mechanism of action, efficacy, and tolerability. Spoke in support of not restricting physician prescribing options for the Anticonvulsants class.
10:45	Dr. Elliott Silbar	Urologist	Vesicare (solifenacin) / Bladder Relaxants Flomax (tamsulin) / Drugs for BPH	Presented superior efficacy, side effect profile, tolerability, and outcomes than other drugs in the class for Vesicare. Presented indications and efficacy for Flomax.
10:50	Cynthia Holmes	Astellas	Vesicare (solifenacin) / Bladder Relaxants	Presented efficacy and indications.
10:55	Tina Hisel	GlaxoSmithKline	Avandia (rosiglitazone) / Hypoglycemics, TZDs Imitrex (sumatriptan) / Antimigraine Agents, Triptans Coreg (carvedilol) / Beta Blockers Lamictal (lamotrigine) / Anticonvulsants	Presented efficacy, unique indications, and effectiveness for Avandia. Presented routes of administration, efficacy, tolerability, and safety for Imitrex. Presented unique indications, efficacy, and compliance advantages for Coreg. Presented indications and side effect profile for Lamictal.
11:05	Sandy Carpenter	Genentech	Nutropin AQ (somatropin) / Growth Hormone	Presented indications, variety of dosing, compliance program, and pen device advantage for Nutropin AQ.
11:10	James Levin, M.D.	Advocate	Hepatitis C Agents	Not restricting physician prescribing options for Peg-intron and Pegasys until additional studies are completed.

Scheduled Time	Name	Company	Product/Class	Notes
11:15	Joseph Goodly, M.D.	Roche	Pegasys (peg-interferon alfa-2a) / Hepatitis C Agents	Presented pharmacokinetics, efficacy, indications, and availability of pre-filled syringe. Testified to the patient benefit of weight-based dosing.
11:20	Dr. Scott McMurray	Alcon	Ciprodex (ciprofloxacin, dexamethasone) / Otics, Antibiotics Floxin (ofloxacin) / Otics, Antibiotics	Presented efficacy, advantages for the treatment of middle ear infections.
11:25	Dr. Lisa Nanovic	Genzyme Corp.	Renagel (sevelamer) / Phosphate Binders Phoslo (calcium acetate) / Phosphate Binders	Presented importance of including a calcium-free phosphate binder.
11:30	William Maierhofer	Advocate – Midelfort Clinic	Fosrenol (lanthanum carbonate) / Phosphate Binders	Presented dosing and toxicity advantages.
11:35	Dr. Vinod Kumar Shah	Advocate	Exubera (insulin for inhalation) / Hypoglycemics, Insulins	Testifying on behalf of his patients. Include Exubera on the PDL. Presented advantages for patients with needlephobia or inability to use syringes.
11:40	Kate Glasenapp	Pfizer, Inc.	Exubera (insulin for inhalation) / Hypoglycemics, Insulins	Testified to the importance of patient choice to gain better compliance with drug regimen.
11:45	Dr. Rajeev Jain	Advocate	Exubera (insulin for inhalation) / Hypoglycemics, Insulins	Testified to the cost of patients not taking insulin because of a fear of needles. Presented improved compliance with the choice of inhaled insulin.
11:50	Dr. Stanley Fudala	Shire	Daytrana (methylphenidate) / Stimulants and Related Agents	Presented advantages of less polypharmacy and potential abuse. Presented dosing and route of administration advantages.
11:55	Dr Todd Mydler	Schering Plough	Peg-Intron (peg-interferon alfa-2b) / Hepatitis C Agents	Presented efficacy, weight-based dosing, and cost advantages.

Discussion of Manufacturer-Specific Supplemental Rebate Amounts (Closed Session)

Secretary Hayden indicated that the next agenda item, a discussion of manufacturer-specific supplemental rebate amounts, was intended for consideration in closed session pursuant to s.19.85(1)(e), Wis. Stats. He further indicated that, under federal and state law, the rebate amounts must remain confidential due to the competitive nature of the rebate agreements and federal drug price confidentiality requirements.

Motion was made to adjourn into closed session by Steve Maike and seconded by Alicia Walker. Secretary Hayden called for a vote on the motion.

Voting results were:

- Tom Frazier – aye
- Steve Maike – aye
- Alicia Walker – aye
- Lawrence Fleming – aye
- Bradley Fedderly – aye
- Tom Hirsch – aye
- Kevin Izard – aye
- Kellianne O’Brien – aye
- Michael Witkovsky – aye
- Rosanne Barber – aye

There were no votes opposed and no abstentions.

Therapeutic Class Reviews, Committee Discussion, and Response to Proposal (Open Session)

ACE Inhibitors/CCB Combinations (High blood pressure)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
TARKA (ORAL)	ON	Yes	
LOTREL (ORAL)	ON	Yes	
LEXXEL (ORAL)	OFF	No	

- Motion to approve- Steve Maike, Tom Frazier
- There were no votes opposed and no abstentions

Angiotensin Receptor Blockers (High blood pressure)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
BENICAR / BENICAR HCT (ORAL)	ON	Yes	
AVAPRO / AVALIDE (ORAL)	ON	Yes	
DIOVAN / DIOVAN HCT (ORAL)	ON	Yes	
COZAAR / HYZAAR	ON	Yes	

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
(ORAL)			
MICARDIS / MICARDIS HCT (ORAL)	ON	Yes	
TEVETEN / TEVETEN HCT (ORAL)	OFF	No	
ATACAND / ATACAND HCT (ORAL)	OFF	No	

- Motion to approve - Michael Witkovsky, Bradley Fedderly
- There were no votes opposed and no abstentions.

Beta Blockers (High blood pressure and heart failure)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modification
METOPROLOL (ORAL)	ON	Generic	
ATENOLOL (ORAL)	ON	Generic	
PROPRANOLOL (ORAL)	ON	Generic	
PINDOLOL (ORAL)	ON	Generic	
NADOLOL (ORAL)	ON	Generic	
SOTALOL (ORAL)	ON	Generic	
ACEBUTOLOL (ORAL)	ON	Generic	
TIMOLOL (ORAL)	ON	Generic	
LABETALOL (ORAL)	ON	Generic	
BETAXOLOL (ORAL)	ON	Generic	
BISOPROLOL (ORAL)	ON	Generic	
TOPROL XL (ORAL)	ON	Yes	
INNOPRAN XL (ORAL)	OFF	No	
LEVATOL (ORAL)	OFF	No	
INDERAL LA (ORAL)	OFF	Yes	No
COREG (ORAL)	ON	Yes	

- The Committee made a modification to the recommendation because there is no clinical advantage of Inderal LA over Toprol XL.
- Motion to approve - Tom Hirsch, Bradley Fedderly
- Motion passed 8-2. Alicia Walker, Rosanne Barber voted nay.
- The generic for Inderal LA is now available. For that reason, Inderal LA will be placed in the DHCF BMN policy effective 03/01/07. The generic product will be 'preferred' on the PDL effective 03/01/07.

Calcium Channel Blockers (High blood pressure)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modification
NICARDIPINE (ORAL)	ON	Generic	
NIFEDIPINE IR (ORAL)	ON	Generic	
VERAPAMIL (ORAL)	ON	Generic	
DILTIAZEM (ORAL)	ON	Generic	
ISRADIPINE (ORAL)	OFF	No-Generic	
NIFEDIPINE ER (ORAL)	ON	Generic	
FELODIPINE ER (ORAL)	ON	Generic	
DYNACIRC CR (ORAL)	OFF	No	
SULAR (ORAL)	ON	Yes	
VERELAN PM (ORAL)	ON	Yes	
CARDIZEM LA (ORAL)	ON	Yes	
COVERA-HS (ORAL)	OFF	No	
NORVASC (ORAL)	ON	Yes	
CARDENE SR (ORAL)	OFF	No	
NIMOTOP (ORAL)	OFF	No	

- Motion to approve - Tom Hirsch, Kevin Izard.
- There were no votes opposed and no abstentions.

Proton Pump Inhibitors (Ulcers and reflux)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
OMEPRAZOLE (ORAL)	OFF	No - Generic	
NEXIUM (ORAL)	ON	Yes	
ZEGERID (ORAL)	OFF	No	
PREVACID CAPSULE (ORAL)	ON	Yes	
ACIPHEX (ORAL)	OFF	No	
PREVACID SOLUTAB (ORAL)	ON	Yes	
PROTONIX (ORAL)	OFF	No	
PREVACID SUSPENSION (ORAL)	ON	Yes	

- Motion to approve - Bradley Fedderly, Michael Witkovsky
- There were no votes opposed and no abstentions.

Lipotropics, Statins (Blood pressure and cholesterol)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modification
LOVASTATIN (ORAL)	ON	Generic	
PRAVASTATIN (ORAL)	ON	No-Generic	
SIMVASTATIN (ORAL)	OFF	Generic	
LESCOL / LESCOL XL (ORAL)	ON	Yes	
LIPITOR (ORAL)	OFF	Yes	
ADVICOR (ORAL)	ON	Yes	
VYTORIN (ORAL)	ON	Yes	
ALTOPREV (ORAL)	ON	Yes	No
CRESTOR (ORAL)	ON	Yes	
CADUET (ORAL)	OFF	No	

- The Committee made a modification to the recommendation because Altoprev has no clinical advantage to lovastatin.
- Motion to approve - Lawrence Fleming, Kevin Izard

Motion passed 6-4. Steve Maike, Tom Hirsch, Kellianne O’Brien, and Rosanne Barber voted nay. Committee members voted against the motion for the following reasons:

- Disagreement that Lipitor should be preferred because of the price difference with the generic drugs.
- Some Committee members felt that generic products should be preferred. There is confusion among patients and pharmacists when generics are not preferred.

Lipotropics, Other (Cholesterol lowering)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
GEMFIBROZIL (ORAL)	ON	Generic	
CHOLESTYRAMINE (ORAL)	ON	Generic	
FENOFIBRATE (ORAL)	NR	Generic	
COLESTIPOL (ORAL)	ON	Generic	
NIASPAN (ORAL)	ON	Yes	
ANTARA (ORAL)	OFF	No	
TRICOR (ORAL)	ON	Yes	
TRIGLIDE (ORAL)	OFF	No	
ZETIA (ORAL)	OFF	No	
OMACOR (ORAL)	OFF	No	
WELCHOL (ORAL)	OFF	No	

- Motion to approve - Lawrence Fleming, Tom Hirsch
- Motion passed 9-1. Alicia Walker voted nay. Alicia Walker voted against the motion because Zetia is not a preferred drug option. The other Committee members stated that

Zetia does not need to be used as a first-line product and Zetia is available using the PA process.

Anticoagulants, Injectables (Clot prevention)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
LOVENOX (SUBCUTANE.)	ON	Yes	
ARIXTRA (SUBCUTANE.)	ON	Yes	
FRAGMIN (SUBCUTANE.)	ON	Yes	
INNOHEP (SUBCUTANE.)	OFF	No	

- Motion to approve - Lawrence Fleming, Bradley Fedderly
- There were no votes opposed and no abstentions.

Anticonvulsants (Seizure disorders)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
PHENOBARBITAL (ORAL)	ON	Generic	
CLONAZEPAM (ORAL)	ON	Generic	
CARBAMAZEPINE (ORAL)	ON	Generic	
VALPROIC ACID (ORAL)	ON	Generic	
PHENYTOIN (ORAL)	ON	Generic	
PRIMIDONE (ORAL)	ON	Generic	
GABAPENTIN (ORAL)	ON	Generic	
MEPHOBARBITAL (ORAL)	ON	Generic	
ETHOSUXIMIDE (ORAL)	ON	Generic	
ZONISAMIDE (ORAL)	ON	Generic	
LAMOTRIGINE (ORAL)	NR	No-Generic	
PHENYTEK (ORAL)	OFF	No	
CELONTIN (ORAL)	ON	Yes	
CARBATROL (ORAL)	ON	Yes	
TEGRETOL XR (ORAL)	OFF	No	
DEPAKOTE SPRINKLE (ORAL)	ON	Yes	
DEPAKOTE (ORAL)	ON	Yes	
GABITRIL (ORAL)	ON	Yes	
EQUETRO (ORAL)	ON	Yes	
DEPAKOTE ER (ORAL)	ON	Yes	
FELBATOL (ORAL)	ON	Yes	
LAMICTAL (ORAL)	ON	Yes	
PEGANONE (ORAL)	ON	Yes	
TRILEPTAL (ORAL)	ON	Yes	
LYRICA (ORAL)	ON	Yes	

TOPAMAX (ORAL)	ON	Yes	
KEPPRA (ORAL)	ON	Yes	
DIASTAT (RECTAL)	ON	Yes	

- Motion to approve - Kevin Izard, Michael Witkovsky
- There were no votes opposed and no abstentions.

Antidepressants, Other (Depression)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
TRAZODONE (ORAL)	ON	Generic	
BUPROPION IR (ORAL)	ON	Generic	
MIRTAZAPINE (ORAL)	ON	Generic	
BUPROPION SR (ORAL)	ON	Generic	
NEFAZODONE (ORAL)	OFF	No-Generic	
VENLAFAXINE (ORAL)	ON	Generic	
WELLBUTRIN XL (ORAL)	OFF	No	
EFFEXOR XR (ORAL)	ON	Yes	
CYMBALTA (ORAL)	OFF	No	
EMSAM (TRANSDERMAL)	NR	No	Yes

- Kevin Izard suggested the Committee include Emsam as a preferred drug because it is a niche drug and has a different route of administration than other drugs in the class.
- Motion to approve - Kevin Izard, Tom Hirsch
- Motion passed 9-1. Alicia Walker voted nay.

Sedative Hypnotics (Insomnia and sleep disorders)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
FLURAZEPAM (ORAL)	ON	Generic	
TEMAZEPAM (ORAL)	ON	Generic	
TRIAZOLAM (ORAL)	ON	Generic	
CHLORAL HYDRATE (ORAL/RECTAL)	ON	Generic	
ESTAZOLAM (ORAL)	ON	Generic	
DORAL (ORAL)	OFF	No	
RESTORIL 7.5 MG (ORAL)	OFF	No	
AMBIEN CR (ORAL)	OFF	Yes	
LUNESTA (ORAL)	ON	No	
ROZEREM (ORAL)	ON	Yes	
AMBIEN (ORAL)	ON	No	Yes

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
SONATA (ORAL)	OFF	No	

- Failed Motion 1 – Tom Hirsch, Alicia Walker. Change Ambien to preferred and change Ambien CR to non-preferred. Motion failed 2-8. Tom Hirsch and Rosanne Barber voted aye.
- Passed Motion 1 – Kevin Izard, Bradley Fedderly. Change Ambien to a preferred agent and do not implement grandfathering in the class. Motion passed 6-4. Kellianne O’Brien, Rosanne Barber, Tom Hirsch, and Michael Witkovsky voted nay.
- Discussion surrounding the motions in this class were the following:
 - Some Committee members felt that including Ambien CR as a preferred agent that the State is sending a message to drug manufacturers that creating drugs to extend patents is appropriate.
 - Generic Ambien will be available in April 2007. This may lead to a large drop in price within the next six months. Committee members felt that if patients moved to Ambien CR, it will be more difficult to move patients to generic Ambien when it becomes available.

Analgesics, Narcotics Short-Acting (Pain control)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
APAP/CODEINE (ORAL)	ON	Generic	
ASA/CODEINE (ORAL)	ON	Generic	
TRAMADOL (ORAL)	ON	Generic	
PROPOXYPHENE/APAP (ORAL)	ON	Generic	
HYDROCODONE/APAP (ORAL)	ON	Generic	
OXYCODONE IR (ORAL)	ON	Generic	
PROPOXYPHENE (ORAL)	ON	Generic	
MORPHINE IR (ORAL)	ON	Generic	
MEPERIDINE (ORAL)	OFF	No-Generic	
OXYCODONE/APAP (ORAL)	ON	Generic	
HYDROMORPHONE (ORAL)	ON	Generic	
PENTAZOCINE/NALOXONE (ORAL)	OFF	No-Generic	
TRAMADOL/APAP (ORAL)	ON	Generic	Off
CODEINE (ORAL)	ON	Generic	
OXYCODONE/ASA (ORAL)	ON	Generic	
DIHYDROCODEINE/APAP/CAFF (ORAL)	ON	Generic	
HYDROCODONE/IBUPROFEN (ORAL)	ON	Generic	
PENTAZOCINE/APAP (ORAL)	OFF	No-Generic	
BUTALBITAL COMPOUND	ON	Generic	

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
W/CODEINE (ORAL)			
LEVORPHANOL (ORAL)	ON	Generic	
FENTANYL (BUCCAL)	OFF	No-Generic	
DARVON-N (ORAL)	OFF	No	
PANLOR DC (ORAL)	OFF	No	
COMBUNOX (ORAL)	OFF	No	
OPANA (ORAL)	NR	No	

- Tom Hirsch suggested the Committee remove tramadol/apap as preferred because of its cost.
- Motion to approve - Tom Hirsch, Lawrence Fleming
- There were no votes opposed and no abstentions.

Analgesics, Narcotics Long-Acting (Pain control)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
METHADONE (ORAL)	ON	Generic	
MORPHINE ER (ORAL)	ON	Generic	
OXYCODONE ER (ORAL)	ON	Generic	
FENTANYL (TRANSDERM.)	ON	Generic	
KADIAN (ORAL)	ON	Yes	
ULTRAM ER (ORAL)	OFF	No	
OPANA ER (ORAL)	NR	No	
OXYCONTIN (ORAL)	NR	No	
AVINZA (ORAL)	OFF	No	

- The motion was made to accept the recommendation with grandfathering. Patients' currently taking oxycodone ER (generic for Oxycontin) will be grandfathered to obtain Oxycontin without any prior authorization restriction. This was recommended because oxycodone ER will no longer be available to patients in the coming year because of a patent decision regarding Oxycontin.
- Motion to approve - Kevin Izard, Bradley Fedderly

Motion passed 8-2. Alicia Walker and Steve Maike voted against the motion.

Antimigraine Agents, Triptans (Migraine headaches)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
IMITREX (NASAL)	ON	Yes	

IMITREX (ORAL)	ON	Yes	
AMERGE (ORAL)	OFF	Yes	
MAXALT / MAXALT MLT (ORAL)	ON	Yes	
AXERT (ORAL)	ON	Yes	
RELPAK (ORAL)	OFF	No	
FROVA (ORAL)	OFF	No	
ZOMIG / ZOMIG ZMT (ORAL)	OFF	No	
IMITREX (SUBCUTANE.)	ON	Yes	
ZOMIG (NASAL)	OFF	No	

- Motion to approve - Tom Hirsch, Michael Witkovsky
- There were no votes opposed and no abstentions.

Hypoglycemics, Meglitinides (Type II diabetes)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
STARLIX (ORAL)	ON	Yes	
PRANDIN (ORAL)	OFF	No	

- Motion to approve - Lawrence Fleming, Bradley Fedderly
- There were no votes opposed and no abstentions.

Hypoglycemics, Thiazolidinediones (Diabetes, oral meds)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
AVANDARYL (ORAL)	ON	Yes	
AVANDAMET (ORAL)	ON	Yes	
ACTOS (ORAL)	ON	Yes	
AVANDIA (ORAL)	ON	Yes	
DUETACT (ORAL)	NR	No	
ACTOPLUS MET (ORAL)	OFF	No	

- Motion to approve - Bradley Fedderly, Lawrence Fleming
- There were no votes opposed and no abstentions.

Multiple Sclerosis Agents (Multiple Sclerosis)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
AVONEX (INTRAMUSC.)	ON	Yes	

BETASERON (SUBCUTANE.)	ON	Yes	
REBIF (SUBCUTANE.)	ON	Yes	
COPAXONE (SUBCUTANE.)	ON	Yes	

- Motion to approve - Bradley Fedderly, Tom Hirsch
- There were no votes opposed and no abstentions.

Antihistamines, Minimally Sedating (Allergies)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
LORATADINE / LORATADINE-D (ORAL)	ON	Generic	
FEXOFENADINE (ORAL)	OFF	No-Generic	
SEMPREX-D (ORAL)	NR	No	
CLARINEX SYRUP (ORAL)	OFF	No	
ZYRTEC SYRUP (ORAL)	OFF	No	
CLARINEX / CLARINEX-D (ORAL)	OFF	No	
ZYRTEC / ZYRTEC-D (ORAL)	OFF	No	
ALLEGRA-D (ORAL)	OFF	No	

- Motion to approve - Lawrence Fleming, Steve Maike
- Motion passed 8-2. Rosanne Barber and Alicia Walker voted against the motion because they wanted Zyrtec to be preferred. Currently, Zyrtec is non-preferred and retained a large market share. The preferred status would remove the hassle of obtaining PA for a large number of patients.

Bladder Relaxants (Incontinence)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
OXYBUTYNIN (ORAL)	ON	Generic	
OXYBUTYNIN ER (ORAL)	ON	Generic	
SANCTURA (ORAL)	ON	Yes	
VESICARE (ORAL)	ON	Yes	
OXYTROL (TRANSDERM.)	ON	Yes	
ENABLEX (ORAL)	ON	Yes	
DETROL LA (ORAL)	OFF	No	
DETROL (ORAL)	OFF	No	

- Motion to approve - Bradley Fedderly, Tom Frazier
- There were no votes opposed and no abstentions.

Drugs for BPH (Enlargement of the prostate)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
DOXAZOSIN (ORAL)	ON	Generic	
TERAZOSIN (ORAL)	ON	Generic	
FINASTERIDE (ORAL)	ON	Generic	
FLOMAX (ORAL)	ON	Yes	
UROXATRAL (ORAL)	ON	Yes	
CARDURA XL (ORAL)	NR	No	
AVODART (ORAL)	ON	Yes	

- Motion to approve - Tom Hirsch, Lawrence Fleming
- There were no votes opposed and no abstentions.

Erythropoiesis Stimulating Proteins (Treatment of low blood levels)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
ARANESP (INJECTION)	ON	Yes	
PROCRIT (INJECTION)	ON	Yes	
EPOGEN (INJECTION)	OFF	No	

- Motion to approve - Kevin Izard, Michael Witkovsky
- There were no votes opposed and no abstentions.

Growth Hormone (Growth deficiencies in children)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
TEV-TROPIN (INJECTION)	ON	Yes	
SAIZEN (INJECTION)	ON	Yes	
GENOTROPIN (INJECTION)	OFF	Yes	
NUTROPIN AQ (INJECTION)	ON	Yes	
SEROSTIM (INJECTION)	OFF	No	
NORDITROPIN (INJECTION)	ON	No	
NUTROPIN (INJECTION)	OFF	No	
HUMATROPE (INJECTION)	OFF	No	
ZORBTIVE (INJECTION)	NR	No	

- Motion to approve - Lawrence Fleming, Tom Frazier
- There were no votes opposed and no abstentions.

Hepatitis C Agents (Viral infection of the liver)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
RIBAVIRIN (ORAL)	ON	Generic	
PEGASYS (SUBCUTANE.)	ON	Yes	
REBETOL (ORAL)	ON	No	
PEG-INTRON REDIPEN (SUBCUTANE.)	ON	Yes	
PEG-INTRON (SUBCUTANE.)	ON	Yes	
COPEGUS (ORAL)	ON	No	
INFERGEN (SUBCUTANE.)	OFF	No	

- Motion to approve - Tom Hirsch, Rosanne Barber
- There were no votes opposed and no abstentions. Michael Witkovsky was absent.

Otics, Fluoroquinolones (Topical antibiotics for ear infection)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
FLOXIN (OTIC)	ON	Yes	
CIPRODEX (OTIC)	ON	Yes	
CIPRO HC (OTIC)	OFF	No	

- Motion to approve - Lawrence Fleming, Tom Frazier
- There were no votes opposed and no abstentions. Michael Witkovsky was absent.

Acne Agents, Topical (Acne)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
ERYTHROMYCIN (TOPICAL)	ON	Generic	
CLINDAMYCIN PHOSPHATE (TOPICAL)	ON	Generic	
BENZOYL PEROXIDE (TOPICAL)	ON	Generic	
TRETINOIN (TOPICAL)	ON	Generic	
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	ON	No-Generic	
AKNE-MYCIN (TOPICAL)	ON	Yes	
CLINAC BPO (TOPICAL)	OFF	Yes	
AZELEX (TOPICAL)	ON	Yes	
NUOX (TOPICAL)	ON	No	
RETIN-A MICRO (TOPICAL)	ON	Yes	
ZACLIR (TOPICAL)	OFF	No	

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
BREVOXYL (TOPICAL)	OFF	No	
BENZAMYCINPAK (TOPICAL)	OFF	No	
DIFFERIN (TOPICAL)	OFF	No	
NEOBENZ MICRO (TOPICAL)	NR	No	
TAZORAC (TOPICAL)	ON	Yes	
BENZIQ (TOPICAL)	NR	No	
KLARON (TOPICAL)	OFF	No	
SULFOXYL (TOPICAL)	OFF	No	
TRIAZ (TOPICAL)	OFF	No	
CLINDAGEL (TOPICAL)	OFF	No	
INOVA (TOPICAL)	NR	No	
BENZAACLIN (TOPICAL)	NR	No	
ZODERM REDI-PADS (TOPICAL)	OFF	No	
DUAC (TOPICAL)	NR	No	
INOVA 4/1 (TOPICAL)	NR	No	
EVOCLIN (TOPICAL)	OFF	No	

- Motion to approve - Tom Hirsch, Tom Frazier
- There were no votes opposed and no abstentions.

Phosphate Binders (Removal of phosphate in kidney disease)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
PHOSLO (ORAL)	ON	Yes	
RENAGEL (ORAL)	ON	Yes	
FOSRENOL (ORAL)	OFF	No	Yes

- The Committee recommended adding Fosrenol as a preferred drug because of its different mechanism of action and its appropriate use by nephrologists.
- Motion to approve - Tom Hirsch, Lawrence Fleming
- There were no votes opposed and no abstentions.

Ulcerative Colitis (Inflammation and sores of the intestine)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
SULFASALAZINE (ORAL)	ON	Generic	
MESALAMINE (RECTAL)	ON	Generic	

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
DIPENTUM (ORAL)	ON	No	
COLAZAL (ORAL)	OFF	Yes	
ASACOL (ORAL)	ON	Yes	
PENTASA (ORAL)	ON	No	
CANASA (RECTAL)	ON	Yes	

- Motion to approve - Rosanne Barber, Tom Frazier
- There were no votes opposed and no abstentions.

Noxafil – Antifungals, Oral (Nail fungus and other fungal infections)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
FLUCONAZOLE (ORAL)	ON	Generic	
KETOCONAZOLE (ORAL)	ON	Generic	
NYSTATIN (ORAL)	ON	Generic	
CLOTRIMAZOLE (MUCOUS MEM)	ON	Generic	
GRISEOFULVIN SUSPENSION (ORAL)	ON	Generic	
ITRACONAZOLE (ORAL)	ON	Generic	
GRIS-PEG (ORAL)	ON	Yes	
GRIFULVIN V TABLETS (ORAL)	OFF	No	
LAMISIL (ORAL)	OFF	No	
ANCOBON (ORAL)	OFF	No	
NOXAFIL (ORAL)	NR	No	
VFEND (ORAL)	ON	Yes	

- Motion to approve - Tom Frazier, Michael Witkovsky
- There were no votes opposed and no abstentions.

Xolegel – Antifungals, Topical (Skin fungal infections)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
NYSTATIN/TRIAMCINOLONE (TOPICAL)	ON	Generic	
CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	ON	Generic	
NYSTATIN (TOPICAL)	ON	Generic	
ECONAZOLE (TOPICAL)	ON	Generic	

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
KETOCONAZOLE SHAMPOO (TOPICAL)	ON	Generic	
KETOCONAZOLE CREAM (TOPICAL)	ON	Generic	
CICLOPIROX CREAM/SUSPENSION (TOPICAL)	ON	Generic	
EXELDERM (TOPICAL)	ON	No	
OXISTAT (TOPICAL)	OFF	No	
MENTAX (TOPICAL)	OFF	No	
NAFTIN (TOPICAL)	OFF	No	
ERTACZO (TOPICAL)	OFF	No	
LOPROX SHAMPOO (TOPICAL)	ON	No	
XOLEGEL (TOPICAL)	NR	No	
LOPROX GEL (TOPICAL)	ON	No	
VUSION (TOPICAL)	OFF	No	
PENLAC (TOPICAL)	OFF	No	

- Motion to approve - Tom Frazier, Michael Witkovsky
- There were no votes opposed and no abstentions.

Zelapar, Azilect – Antiparkinson’s Agents (Parkinson ’s disease)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
BENZTROPINE (ORAL)	ON	Generic	
TRIHENXYPHENIDYL (ORAL)	ON	Generic	
SELEGILINE (ORAL)	ON	Generic	
CARBIDOPA/LEVODOPA (ORAL)	ON	Generic	
PERGOLIDE (ORAL)	ON	Generic	
KEMADRIN (ORAL)	ON	Yes	
REQUIP (ORAL)	ON	Yes	
MIRAPEX (ORAL)	ON	Yes	
PARCOPA (ORAL)	OFF	No	
ZELAPAR (ORAL)	NR	No	
COMTAN (ORAL)	ON	Yes	
STALEVO (ORAL)	ON	Yes	
TASMAR (ORAL)	OFF	No	
AZILECT (ORAL)	NR	No	Yes

- The Committee recommended adding Azilect as a preferred drug to help postpone the use of the carbidopa/levodopa for the treatment of Parkinson 's disease.
- Motion to approve - Tom Frazier, Michael Witkovsky
- Motion passed 9-1. Steve Maike voted nay.

Exubera – Hypoglycemics, Insulins (Diabetes)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
HUMULIN (SUBCUTANE.)	ON	Yes	
HUMALOG (SUBCUTANE.)	ON	Yes	
NOVOLIN (SUBCUTANE.)	OFF	No	
NOVOLOG (SUBCUTANE.)	OFF	No	
LEVEMIR (SUBCUTANE.)	ON	Yes	
LANTUS (SUBCUTANE.)	ON	Yes	
NOVOLOG MIX 70/30 (SUBCUTANE.)	OFF	No	
HUMALOG MIX 75/25 (SUBCUTANE.)	ON	Yes	
APIDRA (SUBCUTANE.)	OFF	No	
SYMLIN (SUBCUTANE.)	ON	Yes	
EXUBERA (INHALATION)	NR	No	
BYETTA (SUBCUTANE.)	ON	Yes	

- The Committee recommended making specific clinical prior authorization for this drug.
- Motion to approve – Lawrence Fleming, Bradley Fedderly
- Motion passed 7-3. Alicia Walker, Rosanne Barber, and Tom Frazier against the motion because they favored making the drug preferred. Exubera has a different route of administration from any other insulin. It is also the first inhaled insulin available for patients who are afraid of needles or do not have the ability to inject themselves with insulin.

Daytrana – Stimulants and Related Agents (ADD and ADHD)

Brand Name	Current PDL Status	PDL Recommendation	Committee Modifications
METHYLPHENIDATE (ORAL)	ON	Generic	
AMPHETAMINE SALT COMBO (ORAL)	ON	Generic	
METHYLPHENIDATE ER (ORAL)	ON	Generic	

DEXTROAMPHETAMINE (ORAL)	ON	Generic	
PEMOLINE (ORAL)	OFF	No-Generic	
FOCALIN (ORAL)	ON	Yes	
ADDERALL XR (ORAL)	ON	Yes	
FOCALIN XR (ORAL)	ON	Yes	
DAYTRANA (TRANSDERMAL)	NR	No	
CONCERTA (ORAL)	ON	Yes	
METADATE CD (ORAL)	ON	Yes	
RITALIN LA (ORAL)	ON	No	
STRATTERA (ORAL)	OFF	No	
DESOXYN (ORAL)	OFF	No	
PROVIGIL (ORAL)	OFF	No	

- Motion to approve - Bradley Fedderly, Lawrence Fleming
- There were no votes opposed and no abstentions.

Closing

The next meeting is in August 15, 2007, in Madison. Secretary Hayden thanked the Committee for its service, participation and attentiveness throughout the day. Secretary Hayden adjourned the meeting.